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  46	
 47	
Abstract 48	
 49	
Background The growing demand for cancer genetic services has led to 50	
suggestions for the involvement of general practitioners. How and in which 51	
conditions they can be involved need to be defined and there may be important 52	
barriers to implementation. 53	
 54	
Aim To review the tools available, clinicians’ attitudes and experiences, and the 55	
effects on patients of genetic cancer risk assessment in general practice. 56	
 57	
Design and setting Systematic review 58	
 59	
Method: Searching MEDLINE/Ovid, EMBASE, Cochrane Library, CINAHL and 60	
PsycInfo databases and grey literature from 1996 to December 2017. Study quality 61	
was assessed with relevant Critical Appraisal Skills Programme (CASP) tool 62	
checklists and a narrative synthesis of fiindings was conducted. 63	
 64	
Results: 40 studies were included. There was a variety of tools available for genetic 65	
cancer risk assessment in general practice, both testing and screening, principally 66	
for breast, breast-ovarian and colorectal cancer risk. Practitioners often reported low 67	
knowledge and confidence to engage with genetic cancer risk assessment, and 68	
despite barriers of time pressure, and worries about confidentiality especially 69	
concerning impact of results for family members, some recognised potential 70	
importance relating to such a development of the GP’s role. Studies found few 71	
reported benefits for patients. Concerns about negative impacts on patient anxiety 72	
and cancer worries were largely not borne out. 73	
 74	
Conclusion General practitioners may have a potential role in identifying patients at 75	
risk of hereditary cancer that can be facilitated by family history tools. There is 76	
currently insufficient evidence to support implementation of population-wide 77	
screening for genetic cancer risk within the competing demands of general practice.  78	
  79	
How this fits in 80	
 81	
Cancer incidence is rising across the world and genetic risk is a significant 82	
contributor. Cancer risk screening and testing is a potential role for General 83	
practitioners (GPs). Several tools are available but none is superior. GPs identify 84	
needs for more education to improve their knowledge and confidence regarding 85	
cancer genetic risks before wider implementation. 86	
 87	
  88	
INTRODUCTION 89	
 90	
According to the World Health Organization, one in six deaths is due to cancer and 91	
number of new cases is expected to rise by 70% over the next two decades. In UK, 92	
5% of patients with bowel cancer have a family history of bowel cancer, 3% of breast 93	
cancers are associated with inherited faulty genes and 10% of melanoma cases are 94	
also associated with a family history of the disease1. In those cases and other 95	
cancers in which genetic risks are involved, earlier detection and treatment could 96	
reduce cancer mortality.  97	
 98	
There is an increasing demand for cancer genetic services and the potential 99	
importance of involving general practitioners is recognized2. Patients commonly seek 100	
out information regarding their risks and clinicians need to be able to respond to this 101	
demand. Direct-to-consumer testing is also increasingly available3. In addition to 102	
such ‘testing’, when presented or accessed by patients, there are also potential 103	
opportunities for systematically or opportunistically screening attendees in general 104	
practice, perhaps based on increased familial risk (see Box 1). However, the ways in 105	
which general practitioners might respond to such trends, particularly within the 106	
context of increasingly time- and resource-constrained everyday practice have not 107	
been effectively established4. 108	
 109	
Family medical history is commonly used in general practice and could be regarded 110	
as a genetic screening strategy5,6. This tool needs to be developed and standardized 111	
to optimize health outcomes in those at risk of inherited cancer. General practitioners 112	
are potentially well placed with access to longitudinal comprehensive health records 113	
and their focus on family to recognise individuals at risk7,8. In the UK (National Health 114	
Service), a patient is eligible for a genetic test if: an inherited faulty gene has already 115	
been identified in one of the patient’s relatives or, there is a strong family history of 116	
cancer in his/her family. In these scenarios, patients are referred to specialist 117	
genetics services (33 across UK) for consideration of further genetics tests. 118	
 119	
 120	
Carroll et al suggest GPs have a potential role as gatekeepers in genetic cancer risk 121	
assessment (testing and screening) 9. However, general practitioners may face 122	
challenges regarding this expanding role due to a lack of clinical genetics knowledge, 123	
perceived lack of confidence in the domain, and time constraints3,10–15. There may be 124	
difficulties in considering genetic cancer risk in routine primary care visits, especially 125	
as acute illness is often the priority, and other (e.g. cardiovascular) preventive 126	
measures have greater prominence than genetic risk of cancer. Testing or 127	
screening, leading to preventive measures, will be more successful if cancer genetic 128	
risk is assessed in large segments of society, not only those who are better informed 129	
and actively consult their general practitioner.  130	
 131	
 132	
This study aims to examine and review the tools available, clinicians’ attitudes and 133	
effects on patients of genetic cancer risk assessment in general practice. From this 134	
we aim also to discuss potential roles that general practitioners might play in genetic 135	
cancer risk assessment and whether systematic screening may be feasible and 136	
effective in general practice. 137	
 138	
 139	
To meet these aims, the following research questions were addressed: 140	
1) What tests (medical procedure to detect those at high risk) and tools (support or 141	
format for those procedures) are available for identifying increased genetic risk 142	
of cancer in general practice? 143	
2) What are clinicians’ attitudes towards screening or testing the population groups 144	
for genetic cancer risk? 145	
3) What are the levels of patient knowledge, satisfaction and anxiety in relation to 146	
tests and communication by a general practitioner about cancer risk? What are 147	
patients’ risk perceptions following screening or testing for genetic cancer risk in 148	
primary care? 149	
4) What are the outcomes of referrals to secondary care following genetic cancer 150	
risk identification in general practice? 151	
 152	
  153	
METHOD 154	
 155	
The following databases were electronically searched: MEDLINE/Ovid, EMBASE, 156	
The Cochrane Library, CINAHL and PsycInfo from 1996 to December 2017. The 157	
grey literature was also searched via OpenGrey and The Health Management 158	
Information Consortium (HMIC) database (also to December 2017). The search 159	
strategy was adapted to each database, with layers of terms around: general 160	
practice, cancer, genetics, testing and tools, attitudes, outcomes and effectiveness. 161	
Hand searching of key journals (Family Practice, Genetics in Medicine and British 162	
Journal of General Practice) and reference lists of relevant papers was also 163	
conducted. The search outputs were downloaded and merged into Zotero, where 164	
duplicates were removed. 165	
 166	
Inclusion criteria: 167	
• Study population: 168	
Studies involving adults (age 18 and above), of either gender, considered to be at 169	
high risk of hereditary cancer were eligible for inclusion.  170	
As advocated by Scheuner et al16 high-risk family history characteristics include the 171	
presence of multiple affected first-degree relatives (FDR) or a FDR with age of onset 172	
of 50 years or less. 173	
 174	
And 175	
• Intervention: 176	
Strategies used for cancer genetic risk testing or screening within general practice. 177	
As suggested by Olesen17, general practice (known as family practice in some 178	
countries) was defined as: “the general practitioner is a specialist trained to work in 179	
the front line of a healthcare system and to take the initial steps to provide care for 180	
any health problem(s) that patients may have.” 181	
Or 182	
• Studies assessing outcome variables; 183	
Clinician attitudes to tests for cancer genetic risk assessment, patient outcomes 184	
following such tests or the outcomes of referrals to secondary care after the 185	
intervention in primary care. 186	
 187	
• Study design  188	
A range of study designs was included to address the different questions within the 189	
review: qualitative, focus groups, semi structured interviews, observational / cross-190	
sectional, cluster randomised controlled trial, implementation studies. 191	
 192	
Exclusion criteria: 193	
• Study not based primarily in general practice or separate data relating to GPs not 194	
presented  195	
• Non-cancerous conditions only 196	
• Cancers without a known familial component  197	
• Test activity described only i.e. number of tests undertaken  198	
• Population based screening application only (not involving primary care) 199	
• Non-English language studies 200	
 201	
We wanted to investigate scenarios involving either the identification of patients at 202	
high risk of hereditary cancer in opportunistic health visits with their general 203	
practitioner, or potential broad systematic or opportunistic screening of patient 204	
populations in general practice to identify those at a high genetic cancer risk.  205	
 206	
Assessment of study inclusion  207	
The selection criteria were initially applied independently to all titles and/or abstracts 208	
by BM or FL. Once narrowed down to references that were potentially relevant, full-209	
copy papers were also assessed by a third reviewer (AE) to determine inclusion and 210	
exclusion. Disagreements were resolved through discussion. 211	
 212	
Data extraction  213	
BM or FL extracted all data onto an excel spreadsheet, recording the study title, 214	
aims, design, setting, participants, inclusion and exclusion criteria, nature of 215	
intervention (where applicable), methods, outcome measures, analysis, key findings 216	
and limitations.  217	
 218	
Assessment of methodological quality 219	
The quality of all eligible studies was assessed using the relevant Critical Appraisal 220	
Skills Programme (CASP) tool checklists18, dependent on study design for qualitative 221	
studies or trials.  As there is no CASP tool for observational cross-sectional studies, 222	
common points included within the checklists for observational cohort and case-223	
control study designs were selected and combined. 224	
 225	
Data Synthesis 226	
Due to the heterogeneous nature of the studies included, a narrative synthesis was 227	
undertaken to collate the evidence relating to each of the research questions 19. 228	
Specific sub-groups of studies were assessed and are presented regarding testing 229	
and screening for genetic cancer risk. 230	
 231	
  232	
RESULTS 233	
 234	
Description of studies 235	
Study selection is summarised in Figure 1. A total of 40 articles was included. 236	
Sixteen of these were observational: cross-sectional studies2,20–32 and two 237	
retrospective15,33. There were six qualitative4,9,34–37, including four semi structured 238	
interviews4,34,35,37. There were 13 intervention studies38–50: three validation 239	
studies38,47,50, one before-after49, three hybrid implementation42,45,48, one comparison 240	
against standard care40, two comparative41,44 and three observational studies39,43,46. 241	
Three studies were cluster randomised controlled trials51–53 and two descriptive 242	
feasibility studies54,55. 243	
 244	
Populations studied 245	
All studies involved both male and female patients or their general practitioners, 246	
except for one study with only female patients and female practitioners. Fourteen 247	
studies were carried out in the UK2,4,20–22,25,34,41,44,49–51,54,55, 17 in North 248	
America9,15,23,27–31,35,37,39,42,43,45,48,52,53, two in South America38,47, two in Australia33,36. 249	
The remaining four were conducted in EU40,26,46,32 (Netherlands, Belgium, Spain) and 250	
one study reported data from four countries across Europe24, namely UK, France, 251	
Germany and the Netherlands.  252	
 253	
Methodological quality 254	
The details of studies are contained in Table 1. The included studies were generally 255	
well designed and reported. Recruitment of participants was suitable, and methods 256	
and analyses were described clearly. Studies varied in the generalizability of their 257	
findings to populations beyond those studied.  258	
 259	
 260	
Screening 261	
 262	
1) Method of screening 263	
 264	
A variety of tools, which could be used in general practice for screening genetic 265	
cancer risk was described15,29,30,38,39,42–45,47–50,52–55. Examples of family history 266	
collection tools include Family Healthware52,53, a self-administered web-based tool, 267	
and FHS-738 which comprises seven questions, both cover family history of breast, 268	
ovarian and colorectal cancer, MeTree42,45,48 is a computerized tool stratifying risk of 269	
hereditary cancer syndromes, i.e. breast, ovarian and colorectal cancer, to be 270	
completed at routine visits and to support clinical decisions. Two studies examined 271	
an office screening form for familial breast cancer alone29,30, whilst Walter et al50 272	
developed a family history questionnaire assessing breast and colorectal cancer, to 273	
be completed at a planned data collection session in the general practice surgery. 274	
In 2013, The US Preventive Services Task Force updated their recommendations 275	
and recognised The Ontario Family History Assessment Tool, Manchester Scoring 276	
System, Referral Screening Tool, Pedigree Assessment Tool and FHS-7 as suitable 277	
for primary care providers to screen women and suggest testing for BRCA1 or 2 278	
genes56. 279	
 280	
The Gail risk model provides the basis for a questionnaire implemented by Owens et 281	
al, and which identifies patients deemed high risk for breast cancer. Four studies 282	
described simple postal questionnaires44,49,54,55, with Leggatt et al49,54 screening for 283	
genetic risk assessment of breast and colorectal cancer, House et al55 identifying 284	
those at risk of colorectal cancer alone and Qureshi44 collecting non-specific cancer 285	
family history information. Biswas et al developed and tested a two-stage approach 286	
with three simplified versions of BRCAPRO to reduce the genetic counselling burden 287	
in general practice15. Flória-Santos47 described a self-reported cancer family history 288	
as a tool to detect breast, prostate, and colon cancer, potentially also useful to 289	
screen other hereditary cancer syndromes. 290	
 291	
2) Attitudes 292	
 293	
Of the five studies examining GP attitudes, three addressed attitudes towards the 294	
process of screening patients for inherited cancer risk in general27,28,37 and two 295	
studies reported attitudes towards specific screening tools43,45. Gramling et al28 296	
reported that 87% of 300 GPs surveyed agreed that screening patients for inherited 297	
cancer risk was important to their practice but only 62% were confident in their own 298	
screening effectiveness. Caroll et al37 showed that primary care providers are 299	
prepared to discuss personalised medicine. Another study by Gramling et al27, with a 300	
small sample of US family physicians, showed that the importance physicians placed 301	
on screening was positively related to their beliefs that a high-risk genetic test result 302	
would motivate behaviour change in patients. The methods for screening in question 303	
were not described27,28.  304	
 305	
In contrast, Owens et al43 discussed that some providers were concerned with the 306	
accuracy of the Gail model formula in identifying high risk patients. Furthermore, 307	
there were worries over the time needed to counsel patients newly determined to be 308	
at high risk and about liability for not successfully providing risk counselling. 309	
 310	
Wu et al45 showed that physicians within two primary care clinics initially felt that they 311	
were already collecting high quality family histories and that MeTree would 312	
negatively impact their workflow. They believed that patients would redirect 313	
discussions away from physician priorities to instead focus on MeTree 314	
recommendations. However post-MeTree integration, 86 % of physicians believed 315	
the tool improved the way they practiced medicine, making practice easier and none 316	
reported that it adversely affected their workflow45.  317	
 318	
3) Patient outcomes 319	
 320	
Six studies assessed patient outcomes following the various methods of screening 321	
for genetic cancer risk29,30,39,45,49,53. There was some evidence that screening can 322	
lead to more accurate risk perceptions with risk feedback following an office 323	
screening form, with greater odds of a patient correctly rating their breast cancer risk 324	
as “high” in those who had a first degree relative with breast cancer30. Wang et al 325	
found that in comparison to control patients, those who underestimated their risk and 326	
who were screened using the Family Healthware tool, increased their perceptions of 327	
colon cancer risk, but not regarding breast or ovarian cancer53. However, Baer et al39 328	
found that a higher percentage of patients who had been screened via YHS (Your 329	
Health Snapshot) reported their perceived risk of colon cancer to be above average 330	
(possibly incorrectly) compared to the control group. Wu et al45 found 85% of 1,184 331	
patients believed MeTree generally raised their awareness of both their personal and 332	
family health risk, changing the way they think about health. 333	
 334	
One study also showed that risk feedback following screening was associated with 335	
lower perceived severity of breast cancer but not with the perceived likelihood of 336	
developing breast cancer in the future29. Gramling et al29 also found that patients 337	
who had had family medical history screened recently were less likely to be worried 338	
about developing breast cancer. This association was present even in those at high 339	
risk, although it was stronger for women with a lower risk family history. In contrast, 340	
Laggatt et al found that completing a screening questionnaire and receiving an 341	
assessment of high genetic risk had no significant impact on general anxiety and 342	
cancer worries49. 343	
 344	
4) Outcomes of referrals  345	
 346	
Only one study52 assessed the effectiveness of referrals following screening for 347	
genetic cancer risk. Rubinstein et al52 found that in those at high risk, consultation 348	
rates with genetic specialists did not differ between the group that completed Family 349	
Healthware and the control group. Furthermore, both groups equally increased their 350	
adherence to risk-based colon cancer screening and mammography schedules. 351	
 352	
Testing 353	
 354	
1) Available tests and tools 355	
 356	
Eight tools were described that could be used in general practice for assessing a 357	
genetic risk of cancer. These tools all incorporated family history into their 358	
assessment and some included further decision support and recommendations.  359	
The Gail model43, MeTree42,42,45,48 and FHS-738 were also used for testing. 360	
The GRAIDS20,51 (Genetic Risk Assessment in Genetics) software provides risk 361	
estimates of breast, ovarian and colorectal cancer. RAGS34,41 (Risk Assessment in 362	
Genetics) also addresses familial breast and ovarian cancer and YHS39 (Your Health 363	
Snapshot) calculates inherited susceptibility to colon, lung, breast and prostate 364	
cancer. The set of GP guidelines by de Bock and al40 assesses breast cancer risk 365	
and Qureshi et al’s FHQ44 (family history questionnaire), identifies the presence of 366	
relatives with cancer in general.  367	
 368	
In relation to genomic tests, four studies reported testing for inherited susceptibility to 369	
breast cancer23,24,26,31, and one study included ovarian cancer31. Another study 370	
related to predictive testing more broadly9. The remaining studies referred to the use 371	
of a standard family history for identifying individuals at risk of hereditary breast 372	
cancer21,22,25,29,43 and non-specific cancer2,4,23. 373	
 374	
2) Clinician attitudes 375	
 376	
A range of views of general practitioners to the genetic cancer risk assessment and 377	
testing was evident. Overall, GPs considered genetic risk assessment to be a 378	
potentially important role for them2,9,24–26,37, but the extent to which they believed they 379	
should be involved with genetics varied. Genetic counselling of patients in regard to 380	
their risk and making management decisions was thought to be less appropriate for 381	
GPs, whilst providing emotional support following testing was acknowledged to be 382	
part of their job2,21,23,25,26. 383	
 384	
General practitioners admitted that they found assessing genetic risk difficult34,37 and 385	
felt uncomfortable when doing so because of their lack of knowledge2,4,22. For 386	
instance, Hapgood et al22 showed 89.5% of GPs included in their study incorrectly 387	
categorized a low-risk breast cancer family history as either moderate (52.9%) or 388	
high (36.6%) risk. General practitioners also lacked confidence in their ability to 389	
interpret genetic test results and explain them to patients2,4,21,22,34. Furthermore, 390	
inadequate skills in taking an appropriate family history were highlighted, with GPs 391	
often failing to get sufficient information from patients to appropriately assess their 392	
risk4,23,24. Significant proportions of GPs were unfamiliar with their local cancer 393	
genetics guidelines and knew little of the services that were available to them25,34. 394	
 395	
From the studies included, it appeared that clinicians were commonly also not 396	
confident in discussing the benefits, risks and limitation of genetic testing with 397	
patients2,21,37. They were concerned by the unnecessary anxiety caused by the 398	
process of genetic testing itself, in addition to an increased risk result being received 399	
by patients4,9,20,25,32. The belief that decreased-risk results would create a false 400	
sense of security was also expressed by some GPs. Another further theme that 401	
arose was about ethical implications and fears of legal repercussions after genetic 402	
tests9,44. This particularly derived from concerns that when a positive result from 403	
testing had implications for patients’ families, this generates concerns over patient 404	
confidentiality and how best to inform other family members of their risk9. 405	
 406	
Overall, GPs expressed concern regarding the validity of genomic testing and its 407	
clinical utility. Time constraints were a further reason that practitioners gave for not 408	
being able to sufficiently counsel patients regarding the benefits and risks of genomic 409	
testing or being able to interpret test results sufficiently2,20,34,43,45. Some GPs believed 410	
that they needed education37 before exploring an expanded role, but studies 411	
conflicted for the intentions of GPs in seeking further education4,21,31. For example, 412	
Walter et al25 reported that only a third of practitioners had attended education about 413	
risk management for breast cancer in the last three years.   414	
 415	
Table 2 summarises main findings regarding clinicians’ attitudes towards screening 416	
and testing. 417	
 418	
3) Patient outcomes 419	
 420	
Data about patient knowledge, satisfaction and anxiety in relation to tests and risk 421	
communication were limited. For the GRAIDS software, there were no significant 422	
differences in knowledge scores, but patients referred from intervention practices 423	
had significantly lower cancer worry scores51. There was also no difference in mean 424	
risk perception, although there was a non-significant trend towards more accurate 425	
risk perception, with fewer intervention patients overestimating their risk at the point 426	
of referral51.  427	
 428	
4) Outcomes of referrals  429	
 430	
There were few data evaluating the effectiveness of referrals to secondary care, 431	
following the identification of high genetic risk of cancer in general practice. One 432	
study43 reported that of the patients referred to the breast centre after a high-risk 433	
consultation, only half actually attended for their visits. A retrospective audit in 434	
Australia found that GPs referred the majority of patients to the genetics service and 435	
were also the most likely to refer inappropriately33. 436	
 437	
DISCUSSION 438	
 439	
Summary 440	
There are several tools available to GPs that can enable them to identify genetic risk 441	
of cancer. Most of these involve a family history component, as an effective way of 442	
determining a patient’s risk of hereditary cancer. Regarding our review questions, 443	
there was most evidence about clinician attitudes to cancer genetics, whereby GPs 444	
consider the assessment of genetic risk to be a potentially important job for them. 445	
Lack of confidence and knowledge may be reasons for their reluctance to undertake 446	
an expanded role beyond that of a ‘gatekeeper’. General practitioners were worried 447	
about the impact of genetic risk assessment on patient anxiety32, particularly if 448	
discussions with whole families would then be required. Furthermore, their ability to 449	
adequately explain risk and its implications within short routine appointments was 450	
raised as a concern. The results regarding patient outcomes show that there may be 451	
a link between genetic risk assessment in primary care and lower cancer worry in 452	
patients, but there were not enough data to accurately describe the relationship in 453	
the general practice setting.  454	
 455	
Strengths and limitations 456	
A comprehensive search strategy was developed for high recall (sensitivity), with a 457	
range of databases, grey literature and hand searches of reference lists conducted. 458	
We included studies of various designs in order to gather evidence that addressed all 459	
of our questions. There was considerable heterogeneity in the results, making 460	
statistical analysis unfeasible and a narrative synthesis was conducted. Our inclusion 461	
criteria were applied strictly, with a particular effort made only to include studies that 462	
specified results from general practice. The main weakness of this literature review is 463	
the limited number of studies that were identified for our review. The heterogeneity of 464	
outcomes reported adds further to difficulties in drawing conclusions. We recognise 465	
that the nature of primary care is likely to vary across the many countries in which 466	
the included studies were conducted. This is particularly the case in North America 467	
(concerning “family medicine”, which is the equivalent of general practice in Europe), 468	
from which almost half of the studies derived. Knowledge about genetic cancer risk 469	
and referrals have dramatically changed over the 20 years period13 covered by those 470	
studies reviewed. We also recognize that the studied population is a sub-population 471	
in primary care. Nevertheless, this review still highlights where evidence is lacking. 472	
 473	
Comparison with existing literature 474	
Many studies have shown that GPs lack confidence in their skills involving cancer 475	
genetics2,3,57. Our results regarding clinician attitudes towards cancer genetics are 476	
similar to those of Mathers et al12, who reported GPs’ resistance to clinical genetics 477	
in general. They too showed that GPs believed genetic conditions required complex 478	
knowledge that should be covered by specialist services, as they were worried about 479	
the accuracy of their knowledge. A review by Emery and Hayflick7 in 2001 identified 480	
family history as important and that GPs needed to gain generic knowledge and 481	
skills in the ascertainment of genetic cancer risk. Our review confirms the current 482	
evidence that clinicians’ confidence in their knowledge is usually sub-optimal. 483	
 484	
McClain et al58 investigated six family history screening protocols for breast and/or 485	
ovarian cancer by applying them to family histories taken from four cohorts of women 486	
in a variety of settings. They showed that each of these protocols used alone gave 487	
too many screen-positive results, but when all six protocols agreed, there was a 488	
more acceptable screen-positive rate. Similarly, if some of the genetic cancer risk 489	
screening tools identified in this review were compared directly, a singular composite 490	
screening tool including key items, could potentially be identified. 491	
 492	
Implications for practice and research 493	
Advances in genetic medicine were expected to lead to a shift towards general 494	
practice being more involved with provision of genetic services. General practitioners 495	
are potentially important in identifying patients at increased risk of hereditary cancers 496	
to ensure suitable subsequent management. The value of taking a comprehensive 497	
family history should not be overlooked by clinicians, together with the many other 498	
tools identified in this review that could potentially be used in practice. None of the 499	
tools identified can be recommended for use over another at this stage, but 500	
improving clinician awareness of their existence could support future implementation. 501	
Being able to use one of these tools also implies being able to discuss advantages 502	
and disadvantages of such screening and testing and results with patients. This is a 503	
challenge also concerning test results that may be brought to GPs after direct-to-504	
consumer tests (e.g. 23andme.com). There is little evidence that GPs have the 505	
combined knowledge, confidence, skills, experience or capacity to do this in usual 506	
practice. 507	
 508	
Further studies are needed to evaluate patient outcomes, particularly psychological 509	
impact, of genetic cancer risk screening, particularly if it is to be offered routinely to 510	
patients in general practice. Moreover, it is important to consider acceptability of 511	
such screening to patients in primary care. Research with hard-to-reach groups who 512	
may be less likely to take up screening when offered is also needed.  513	
 514	
General practitioners have a potential role in identifying patients at risk of hereditary 515	
cancer, however family history-taking practices are often inadequate to assess risk. 516	
Consequently, several tools have been developed to help, facilitate and improve 517	
genetic risk assessment in general practice. But, at this current point in time, it is 518	
difficult to support the adoption of routinely available testing or population-wide 519	
screening practices within primary care. Before the implementation of such genetic 520	
risk assessment tools is recommended in practice, further well-conducted studies 521	
are needed to provide evidence of their benefits, particularly on patient outcomes. 522	
General practitioner knowledge and confidence regarding cancer genetics are 523	
barriers that must also be improved if they are to consider an expanded role. 524	
 525	
  526	
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